I
Inne
Biotech startup building a hormone-based mini lab for women
About Inne
Inne is a FemTech company that has developed a home-use minilab for hormone tracking. The system utilizes a daily saliva test to measure progesterone levels, providing women with insights into their menstrual cycle and fertility. This data is then synchronized with a companion mobile application, allowing users to monitor their hormonal patterns, identify their fertile window, and make informed decisions about their reproductive health, including for contraceptive purposes or to aid in conception.
Read full description
The company operates on a direct-to-consumer subscription model. Customers purchase the minilab reader and subscribe to receive the testing strips on an ongoing basis. This model ensures a recurring revenue stream for the company. Inne targets women who are seeking a more natural and data-driven approach to cycle tracking, as an alternative to traditional methods like temperature tracking or hormonal contraception.
The market for Inne is the growing FemTech industry, with a specific focus on fertility and hormone monitoring solutions. The company differentiates itself by offering a non-invasive, saliva-based testing method that directly measures a key hormone, providing a more direct and scientifically-backed insight into the user's cycle than other indirect methods.
At a glance
- Status
- Operational
- Founded
- 2016
- Headquarters
- Berlin, Germany
- Employees
- 181
- Open positions
- 3
- Dealroom signal
- 84.8/100
- Industry
- Health
- Sub-industry
- BioTechnology, Medical Devices, Health Platform
- Sector
- Biotech & Life Sciences, Testing, Fertility, Biotechnology, Remote Monitoring, Femtech
- Technology
- Hardware, Deep Tech, Mobile app
- Business model
- Manufacturing
- Client focus
- b2c
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | May 2022 | $10M | $40M | Rolf Schrömgens · Borski Fund · Calm/Storm Ventures · Taavet Hinrikus | ↗ |
| SERIES A✓Equity / VC | Oct 2019 | $8M | $32M | Monkfish Equity · Tom Stafford · Rolf Schrömgens · Taavet Hinrikus | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Inne is 47K monthly website visits, down 41.3% over the last three months. Inne's team grew 5.2% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A10 investors entered at this stage
Blossom Capital
Monkfish Equity
Tom Stafford
Rolf Schrömgens
Taavet Hinrikus
DSM
Borski Fund
Calm/Storm Ventures
Dr Fiona Pathiraja- DVDSM Venturing
Other known investors5 additional known investors
Hornet Ventures
JVH Ventures
KFLT Angels
non olet
ophelia brown.
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Inne on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Inne’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.